CHLORMERODRIN HG 197
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLORMERODRIN HG 197 is a radiopharmaceutical diagnostic agent approved in 1974 by Bracco, administered via injection for imaging purposes. The mechanism of action and specific clinical indications are not publicly detailed in available data. This is a legacy diagnostic imaging product with a decades-long market presence.
LOE Approaching
As a legacy diagnostic radiopharmaceutical approaching LOE, commercial teams are likely small and focused on maintenance of existing market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers minimal career growth opportunity, with zero linked job openings and a maintenance-focused commercial strategy. Career professionals should expect stable but limited scope—typical of legacy diagnostic products in their twilight years.
Product ManagerRegional Sales Manager
Worked on CHLORMERODRIN HG 197 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.